ChromaDex Corp. (CDXC), a commercial-stage global bioscience company, expects 2024 revenue to grow at a higher rate than the prior year growth of 16%.
The company derives most of its revenue from Tru Niagen, a supplement that is believed to slow or reverse the process of aging. Tru Niagen works by boosting Nicotinamide adenine dinucleotide plus (NAD+) and supports the body's natural cellular energy production.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.